Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (371-380 of 411) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG studyLea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2017
Prognostic factors and treatment outcomes in 444 patients with mucosal melanomaMarkus V Heppt, Alexander Roesch, Benjamin Weide, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionMarkus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
The Journal of Investigative Dermatology|April 19, 2020
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell CarcinomaMaya Farah, Alexandre Reuben, Ivelina Spassova, et al.
Pageof 42

Showing results (371-380 of 411) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG studyLea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2017
Prognostic factors and treatment outcomes in 444 patients with mucosal melanomaMarkus V Heppt, Alexander Roesch, Benjamin Weide, et al.
Science (New York, N.Y.)|September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaEliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionMarkus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
The Journal of Investigative Dermatology|April 19, 2020
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell CarcinomaMaya Farah, Alexandre Reuben, Ivelina Spassova, et al.
Pageof 42